Press Releases

 

GW Files Sativex® Regulatory Submission in Canada for Cancer Pain

19 October 2006

Porton Down, UK, 19 October 2006: GW Pharmaceuticals plc (AIM: GWP) (“GW” or “the Company”) and Bayer HealthCare, Pharmaceuticals Division - Canada (“Bayer”) announce that GW has submitted a regulator... more

Sativex® Data Presented at ECTRIMS European Multiple Sclerosis Congress

3 October 2006

Porton Down, UK, 3 October 2006 – GW Pharmaceuticals plc (AIM: GWP) announces today that results from two Phase III studies of Sativex ® were presented at Europe's leading multiple sclerosis (MS) conf... more

GW Files Sativex® for Approval in Selected European Countries for MS Spasticity

5 September 2006

Porton Down, UK, 5 September 2006 - GW Pharmaceuticals plc (AIM: GWP) (“GW” or “the Company”) today announces that it has filed a regulatory submission in selected European countries for Sativex®, its... more

Start of Second Phase III Trial in MS Neuropathic Pain

9 August 2006

Porton Down, UK, 9 August 2006 - GW Pharmaceuticals plc (AIM: GWP) announces the start of a second pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pai... more

Interim Results For The Six Months Ended 31 March 2006

20 June 2006

Porton Down, UK, 20 June 2006: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new medicines based on cannabis and other controlled drugs, announces its interim results... more

Interim Results For The Six Months To 31 March 2003

19 June 2006

GW Pharmaceuticals plc, the company licensed by the UK Home Office to work with cannabis and a range of controlled drugs for medical research purposes, announces its interim results for the six months... more

Appointment of Adviser

16 May 2006

GW Pharmaceuticals plc (AIM: GWP) is today pleased to announce the appointment of Investec Bank (UK) Limited as Nominated Adviser and Broker to the Company with immediate effect.... more

Preliminary Results from Sativex® Phase III Multiple Sclerosis spasticity study

17 March 2006

Porton Down, UK, 17 March 2006 - GW Pharmaceuticals plc (AIM: GWP) today announces preliminary results from a Phase III study of Sativex® in the relief of spasticity in people with Multiple Sclerosis ... more

Changes to Non-Executive Directors

10 February 2006

GW Pharmaceuticals today announces the appointment of Mr David Morrison as a non-executive director with immediate effect. Mr Morrison replaces Mr Peter Mountford, who today resigns as a non-executive... more

Preliminary Results for the Year Ended 30 September 2005

19 January 2006

GW Pharmaceuticals plc, the company which develops and manufactures a range of new medicines based on cannabis and other controlled drugs, announces its preliminary results for the year ended 30 Septe... more

FDA Accepts Investigational New Drug (IND) Application For Sativex®

4 January 2006

GW Pharmaceuticals (AiM:GWP) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for Sativex®, a cannabis-derived, oro-mucosal ... more

GW Raises $15m (£8.6m) in US Placing

4 January 2006

GW Pharmaceuticals plc (AiM:GWP) today announces that it has signed an agreement with a United States-based institutional investor to raise $15 million (£8.6 million) before expenses through a placing... more
 
 

© GW Pharmaceuticals 2012